Hhlr Advisors, Ltd. Arvinas, Inc. Transaction History

Hhlr Advisors, Ltd.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 12, 2021	SELL	$20.19 - $84.93 $6.31 Million - $26.5 Million	-312,500 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$22.99 - $36.34 $7.18 Million - $11.4 Million	-312,500 Reduced 50.0%	312,500 $7.38 Million
Q2 2020 Aug 14, 2020	SELL	$29.88 - $56.74 $6.88 Million - $13.1 Million	-230,308 Reduced 26.93%	625,000 $21 Million
Q3 2019 Nov 14, 2019	BUY	$21.55 - $27.61 $4.96 Million - $6.36 Million	230,308 Added 36.85%	855,308 $18.4 Million
Q4 2018 Feb 14, 2019	BUY	$11.19 - $18.56 $6.99 Million - $11.6 Million	625,000 New	625,000 $8.03 Million

224

70.9M

1.52M

346K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $986M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Hhlr Advisors, Ltd., based on Form 13F filings with the SEC.

Stay updated on Hhlr Advisors, Ltd. with notifications on news.